Precision Medicine Vision Statement

The World Economic Forum's Global Precision Medicine Council outlines five governance gaps—data sharing, ethical use, trust, access/pricing, and regulatory systems—that impede the widespread adoption of precision medicine. The report argues that more than half the world's population lacks access to these tools and recommends standardizing data, diversifying research populations, and modernizing intellectual property and pricing models to ensure global equity.

• The Council identifies five primary governance gaps that obstruct the implementation of precision medicine: data sharing and interoperability; ethical use of technology; patient and public engagement and trust; access, delivery, value, pricing and reimbursement; and responsive regulatory systems.
• Global access to precision medicine is highly unequal, with more than 50% of the world's population currently unable to access these technologies.
• Data interoperability is hindered by a lack of common standards and 'myopic goals' of independent initiatives. The report advocates for the adoption of FAIR principles (Findability, Accessibility, Interoperability, and Reusability) to enable machine-actionability of structured data.
• Ethical failures in genomic research, such as those involving the San peoples of Southern Africa and the Havasupai tribe, highlight the need for culturally informed informed consent and the just distribution of research benefits to participants.
• Precision medicine research has historically been biased toward populations of European heritage or males, which may reduce the effectiveness of therapies for other global populations. The report calls for prioritizing inclusivity and representativeness in research.
• Public trust is undermined by the lack of transparency in the direct-to-consumer (DTC) genetic testing market, where data may be sold to third parties or accessed by law enforcement without clear disclosure.
• In the United States, the use of surrogate endpoints for fast-track drug approvals often results in a lack of real-world efficacy evidence; between 2008 and 2013, 86% of oncology drugs approved via surrogate endpoints had unknown effects on overall survival or failed to show improvement after four years.
• Innovation in diagnostics is slowed by intellectual property laws, specifically Section 101 of US patent law, which classifies biomarkers and algorithms as 'products of nature' or 'abstract ideas,' making them ineligible for patent protection.
• There is a critical global shortage of genetic counsellors, with only approximately 7,000 across 28 countries as of 2018, necessitating new digital and scalable models for providing genetic advice.
• The report recommends that global regulators explicitly prohibit the use of precision health data for discriminatory purposes, such as setting insurance premiums or enabling a 'surveillance society' via police or state access.

APA

World Economic Forum (2020). Precision Medicine Vision Statement. http://www3.weforum.org/docs/WEF_Global_Precision_Medicine_Council_Vision_Statement_2020.pdf

Chicago

World Economic Forum. Precision Medicine Vision Statement. 2020. http://www3.weforum.org/docs/WEF_Global_Precision_Medicine_Council_Vision_Statement_2020.pdf.

Wikipedia

{{cite report |author=World Economic Forum |title=Precision Medicine Vision Statement |date=May 2020 |url=http://www3.weforum.org/docs/WEF_Global_Precision_Medicine_Council_Vision_Statement_2020.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{worldeconomicforum2020precision, author = {{World Economic Forum}}, title = {{Precision Medicine Vision Statement}}, institution = {World Economic Forum}, year = {2020}, month = may, url = {http://www3.weforum.org/docs/WEF_Global_Precision_Medicine_Council_Vision_Statement_2020.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }